Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.54 |
| ▸ | OGFRL1 | Q5TC84 | 12/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | VPS4B | O75351 | 1/20 | 0.34 |
| ▸ | VCP | P55072 | 1/20 | 0.34 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL706789 | 0.85 | OPRM1 (0.56) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL699715 | 0.79 | OPRM1 (0.65) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL700102 | 0.79 | OPRM1 (0.58) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL699742 | 0.78 | OPRM1 (0.55) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL3567022 | 0.76 | OPRM1 (0.60) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL3559035 | 0.76 | OPRM1 (0.68) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL2436266 | 0.76 | OPRM1 (0.57) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL702288 | 0.75 | OPRM1 (0.56) | OPRM1OGFRL1ALDH1A1GAAHTR1D | |
| SCHEMBL2439375 | 0.75 | OPRM1 (0.58) | OPRM1OGFRL1OPRL1OPRD1OPRK1 | |
| SCHEMBL699427 | 0.75 | OPRM1 (0.56) | OPRM1OGFRL1OPRL1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124788-B2 | Spirocyclic cyclohexane compounds with analgesic activity | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-20090111842-A1 | SPIROCYCLIC CYCLOHEXANE COMPOUNDS WITH ANALGESIC ACTIVITY | GRUENENTHAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111842-A1 | SPIROCYCLIC CYCLOHEXANE COMPOUNDS WITH ANALGESIC ACTIVITY | OPRK1, OPRL1, OPRD1 | OPRM1 9/4885OGFRL1 163/4885OPRL1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.